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summaryAbstract Background: Currently, there are between 300,000 and 500,000 childhood cancer
survivors (CCSs) in Europe. A significant proportion is at high risk, and at least 60% of them
develop adverse health-related outcomes that can appear several years after treatment comple-
tion. Many survivors are unaware of their personal risk, and there seems to be a general lack
of information among healthcare providers about pathophysiology and natural history of
treatment-related complications. This can generate incorrect or delayed diagnosis and treat-
ments.
Method: The Survivorship Passport (SurPass) consists of electronic documents, which sum-
marise the clinical history of the childhood or adolescent cancer survivor. It was developed
by paediatric oncologists of the PanCare and SIOPE networks and IT experts of Cineca,
together with parents, patients, and survivors’ organisations within the European Union
efunded European Network for Cancer research in Children and Adolescents. It consists
of a template of a web-based, simply written document, translatable in all European lan-
guages, to be given to each CCS. The SurPass provides a summary of each survivor’s clinical
history, with detailed information about the original cancer and of treatments received,
together with personalised follow-up and screening recommendations based on guidelines
published by the International Guidelines Harmonization Group and PanCareSurFup.
Results: The SurPass data schema contains a maximum of 168 variables and uses internation-
ally approved nomenclature, except for radiotherapy fields, where a new classification was
defined by radiotherapy experts. The survivor-specific screening recommendations are mainly
based on treatment received and are automatically suggested, thanks to built-in algorithms.
These may be adapted and further individualised by the treating physician in case of special
disease and survivor circumstances. The SurPass was tested at the Istituto Giannina Gaslini,
Italy, and received positive feedback. It is now being integrated at the institutional,
regional and national level.
Conclusions: The SurPass is potentially an essential tool for improved and more harmonised
follow-up of CCS. It also has the potential to be a useful tool for empowering CCSs to be
responsible for their own well-being and preventing adverse events whenever possible. With
sufficient commitment on the European level, this solution should increase the capacity to
respond more effectively to the needs of European CCS.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Survival after childhood cancer has improved substan-
tially over the past five decades, and currently, it is
estimated that there are between 300,000 and 500,000
childhood cancer survivors (CCSs) in Europe [1e3], with
a median age between 25 and 29 years, and approxi-
mately 8000 to 10,000 new survivors added every year [4].
Research has shown that certain subgroups of this
growingpopulation aremore vulnerable andhave ahigher
risk of experiencing adverse health-related and quality of
life outcomes than their peers [1,5e7]. Some adverse ef-
fects can appear soon, but many develop several years or
even decades after treatment completion [8,9].
Long-term follow-up (LTFU) is therefore crucial well
beyond the end of the paediatric age, in particular
during the critical transition period from childhood to
adult care [10,11]. However, several reports [12e14]
have shown that many survivors are unaware of their
personal risk of developing specific late effects. In
addition, there seems to be a general [15] lack ofinformation among healthcare providers about the
pathophysiology and natural history of treatment-
related complications. This can result in incorrect or
delayed diagnosis and treatments [9]. Moreover, infor-
mation about anticancer treatment given many years
earlier may have been forgotten or be insufficiently
documented and thus unavailable to medical teams or
the survivors themselves. There is particular difficulty
when the survivor moves from paediatric to adult
healthcare services or to a different region or country. In
the latter case, a translation may be required to inform
healthcare professionals accordingly.
We report here about the Survivorship Passport
(SurPass) application developed as part of the European
Unionefunded (FP7-HEALTH-F2-2011 no. 261474)
European Network for Cancer research in Children and
Adolescents (ENCCA, www.encca.eu) project, the
PanCare Childhood and Adolescent Cancer Survivor
Care and Follow-up Studies project (PanCareSurFup,
www.pancaresurfup.eu e HEALTH 2010 2.4.1-7, no.
257505-2), and the European Expert Paediatric
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Treatment (ExPO-r-Net project (Chafea Project Grant
Nr: 2013 12 07), aiming to provide each CCS with an
electronic treatment summary including individualised
recommendations for follow-up as well as respective
translations in European languages.2. Methods
The SurPass concept aimed to define a common
template of a document to be given to the individual
patient after the elective end of treatment therapies. The
document had to fulfil the following set of requirements:
i) be available on paper and digitally; ii) be written in a
simple way, containing cancer history and therapy in-
formation according to a common coding scheme
whenever possible; iii) provide advice and guidance on
patient-specific LTFU of possible late effects according
to internationally accepted standard guidelines for
follow-up and care, as available and iv) be translatable
to all EU languages.
Major developments included the following: first,
relevant stakeholders of various European institutions
and communities actively participated, and paediatric
oncology late effect experts (see acknowledgements),
parents’ and survivors’ organisations (Childhood Can-
cer International (CCI) and the Pan-European Network
for Care of Survivors after Childhood and Adolescent
Cancer (PanCare)) were actively involved. The variables
summarising the details about the original cancer and
associated treatments were defined for the summary
section of the SurPass document. When available,
internationally approved nomenclature and coding
schemes were adapted for each variable. Otherwise, a
specific coding system was developed.
Second, Cineca IT experts designed the electronic
infrastructure for the SurPass data collection and
insertion, taking into consideration security and privacy
issues, the possibility of data transfer from already
available clinical datasets and multilanguage support.
The resulting electronic platform had to be fully
compliant with the latest national and international data
privacy regulations.
Third, the screening recommendations for possible
late complications of treatment were developed by
PanCareSurFup in collaboration with the International
Guideline Harmonization Group (IGHG) (www.ighg.
org/international-guideline-harmonization-group/
methods/process) [16].
Finally, these components were integrated to form
the SurPass structure and ready-to-use tool.
During the phase of prototype development, in-
stitutions interested in the SurPass were given a per-
sonal password to test remote data entry and built-in
algorithms for defining personal recommendations.
Over 50 accounts were activated, and feedback fromusers was then considered for further implementation
and improvements. Furthermore, the possibility of
automatic download from databases of the clinical trial
in which the survivor was previously enrolled was also
tested.
When the first SurPass prototype had been developed,
a test phase was carried out at one institution (Istituto
Giannina Gaslini, Italy) after ethics committee approval
was granted. In this test, after obtaining informed con-
sent from the survivor or, for those underage or lacking
capacity, their parents, the SurPass was handed out to
survivors during a regular late effects follow-up consul-
tation by the treating oncologist or the late effects expert
in the presence of a nurse and a psychologist. A 27-
question Likert questionnaire (Supplementary Table 1)
was then sent by mail 3 months after the SurPass delivery
to evaluate the psychological and emotional impact on
the survivor and/or their relatives.3. Results
3.1. Treatment summary template
The SurPass data schema (Fig. 1) contains a total of 168
variables, divided into five sections: i) demographic data;
ii) tumour description and other concurrent diseases,
either cancer predisposition syndromes (e.g. ataxia tel-
angiectasia) or other clinical conditions not cancer
associated (e.g. diabetes) if any; iii) front-line treatment
for the primary main tumour and salvage treatment in
case of progression/relapse before the first elective end of
treatment, with details on iiia) chemotherapy, iiib) stem
cell transplantation, iiic) radiation therapy, iiid) major
surgery, iiie) other relevant clinical events that occurred
during treatment and iiif) medical prescriptions at the
time of elective end of treatment; iv) screening
recommendations and v) follow-up. Variables were
translated from English into several European languages,
including Croatian, Czech, Dutch, French, German,
Italian, Lithuanian and Spanish, within the scope of the
European project ExPO-r-Net (www.expornet.eu).
In case of a relapse or of a subsequent malignant
neoplasm (SMN) after the end of first-line treatment,
the SurPass may be updated by the treating physician
once the new information about site and type of relapse
or SMN and related salvage treatments becomes avail-
able. Individualised screening recommendations may be
affected by the additional salvage treatments. Therefore,
updated and adapted new screening recommendations
are generated and may be integrated into the updated
SurPass. Because some survivors might become lost to
follow-up, a statement that ‘information is updated to
the best of our knowledge at the date of this document
issue/update’ is included.
Tumour description is based on the International
Classification of Diseases for Oncology 3rd edition, 1st
Fig. 1. Data schema of the Survivorship Passport.
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available in different languages, thanks to a licence
agreement with the World Health Organization (En-
glish and French) or national groups (Spanish, Italian,
German, Lithuanian and Hungarian), and the Inter-
national Classification of Childhood Cancer (ICCC)
3rd edition. To facilitate understanding by survivors, an
algorithm defines the most usual lay term to describe
the specific tumour either using the main or extended
classification table of ICCC-3. In the case of ‘unspeci-
fied’ or ‘other’ tumours in the ICCC-3 classification, the
ICD-O-3 morphology term is used. Information can
also be collected about somatic genetic or molecular
markers of the tumour. ICD-9 or ORPHANET codes
are used to identify other diseases and/or predisposing
syndromes.
The Anatomical Therapeutic Chemical drug (www.
atccode.com) classification has been used to identify
each drug used to treat the cancer. Synonyms and/or
commercial names for each compound have also been
included into the system to assign drugs that might
have been reported with different names (e.g. Endoxan,
Cytoxan) to the same compound (cyclophosphamide).
For survivors having undergone stem cell trans-
plantation, information on the date of the procedure,
source of cells, conditioning regimen (to be included in
the cumulative dose calculation of chemo-immune-
radio-therapy), GVHD grade and type is included in
the SurPass.In the absence of a radiotherapy coding system,
radiotherapy experts found it necessary to adapt the
radiotherapy classification scheme as in use in North
America (www.survivorshipguidelines.org), which is
based on body regions rather than radiation fields.
Because the level of detail on the treatment field varied
greatly across decades, and continues to change, we
drafted a three-tier scheme, where level one addresses
large anatomical areas, level two whole organs, and level
three defines parts of those organs. A special code was
also generated for specific, commonly used large radio-
therapy fields that include multiple anatomical sites (e.g.
total body irradiation, mantle and inverted Y). For
survivors treated many years ago, only level-one infor-
mation might be available, but this is often sufficient for
linkage with the current follow-up surveillance guidelines
[16]. More patient-specific text, imaging or modern
radiotherapy plans showing dose/volume histograms and
organs at risk (OAR) can also be added as summary
attachments, although such information cannot be
incorporated in the standardised coding scheme at pre-
sent. Details will be reported in a separate publication.
The variety and scope of surgical procedures is too
complex for appropriate coding. Therefore, space (text
field) for non-coded information to report about the
surgical intervention and complications, if any occurred
during the procedure, is provided. However, it is
possible to identify organs either enucleated/amputated
and/or prostheses insertion. In addition, there is space to
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insertion of a central venous catheter, and so on.
Information is also provided about supportive care
with blood derivates (e.g. packed red cells) and date of
last transfusion. In the section ‘other relevant clinical
events,’ the SurPass allows reporting of events during
treatment (e.g. seizures or admission to intensive care
unit) that are considered to be important for general
medical follow-up purposes.
3.2. Follow-up recommendations
Organ-specific surveillance recommendations imple-
mented into the SurPass are based on guidelines devel-
oped by the IGHG and PanCareSurFup consortia [16].
Each organ-specific guideline defines the following: i)
who needs surveillance; ii) what is the most appropriate
test for screening; iii) when and at what frequency
screening should be initiated and or ended and iv) what
should be done if abnormalities are identified.
Subjects at risk for each outcome (e.g. cardiomyopathy,
subsequent breast cancer, male or female gonadal
toxicity and thyroid cancer) [17e21] are identified by using
automated algorithms built into the system, which are
based on the risk group definitions reported in the respec-
tive guidelines. The published LTFU care for childhood,
adolescent and young adult cancer survivor guidelines can
be found here http://www.ighg.org/guidelines/
The system provides the strength of the screening
recommendation. According to IGHG criteria [16], four
levels of strength of recommendations to enter a specific
screening program are reported and highlighted with a
colour code: strong (green), moderate (yellow) or weak
(orange) or a recommendation not to do (red) because
of the expectation of more harm than benefit of such
testing. The treating physician can also assign other
screening recommendations, based on survivor-specific
medical history (e.g. complications during treatment).
A shared decision to enter the screening program for
each organ at risk identified by the system will be made
by the treating physician together with the survivor and/
or their parents based on the strength of recommenda-
tions, survivor’s wishes, any other possible risk factor
(e.g. family history) and local circumstances.
For each guideline, an organ-specific brochure has
been prepared by paediatric oncologists of the PanCare
network after approval by the respective guideline group
(in paper and electronic format) to summarise the per-
sonal recommendations in lay language with a question-
and-answer format (examples in online Figs. 1e4). A
general description of the pathophysiology of the organ
at risk is also included. The SurPass platform automat-
ically suggests the recommendations to be delivered to
the survivor according to the treatment received. The
treating physician approves the personalised recommen-
dations and issues the personalised SurPass, bearing the
survivor’s name and SurPass number. In addition, theorgan-specific brochure with the survivor name and
SurPass number can be printed. Each brochure is origi-
nally prepared in English and then translated into several
European languages by native speakers in the affiliated
consortia and/or translators of the UN Volunteers Pro-
gramme (https://unv.org). The brochures are currently
available in the following languages: Croatian, Czech,
Dutch, English, French, German, Italian, Lithuanian
and Spanish. Translations into Greek, Hungarian,
Polish, Portuguese, Swedish and Hebrew are in progress.
Information regarding timing and results of screening
tests performed after SurPass delivery can be uploaded
by the treating physician or late-effects clinic staff into
the follow-up form and stored. At each visit, the system
reports the clinical summary of the previous evaluation
and requests updated medical and socioeconomic his-
tory, results of physical examination and of other eval-
uations performed during the visit. A new summary will
then be prepared by the physician, after evaluation of all
new information. Any chronic condition (either newly or
already diagnosed) can be reported and categorised
through identification of i) system affected (e.g. cardio-
vascular); ii) organ or system affected (e.g. heart, vessels)
and iii) details (e.g. cardiomyopathy, arrhythmia and
hypertension).3.3. IT infrastructure development
The web-based platform provides a secure online data-
base that enables the collection and storage of all the
data and images in a standard format, allowing the self-
generation of the SurPass document (Fig. 2).
The web-based platform can be delivered from the
Italian Cineca-certified data centre in SaaS (Software as a
Service) mode or can be installed at any local data center
that can guarantee compliance to security and quality
standards if it is requested according to the country-
related needs. In addition, personalisation can be done to
activate the platform in a dedicated environment.
Fig. 3 summarises the SurPass data flow and access.
Patient data can be either automatically imported from
already existing electronic health records, using interop-
erability standards and data linkage procedures, or
inserted and completed through remote data input. Per-
sonal data are encrypted, and the platform is compliant
with the highest security standards (using HTTP and SSL
encryption standards) and data quality procedures, ac-
cording to ISO270001 certification (https://www.cineca.it/
en/content/certifications). Privacy is enforced with role-
based user security (survivor, health professional and
data manager), authentication, identification and
authorisation mechanisms to share and store data.
Data ownership is regulated in compliance with the
European Directive 2016/679, which went into effect on
25 May 2018 (GDPR): individual centres/survivors
retain data ownership; the software provider must be
Fig. 2. Survivorship Passport layout and template of a hypothetical survivor.
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Fig. 3. Survivorship Passport data flow and access.
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management of the survivors’ data.
When the treating physician issues the personalised
SurPass and recommendations to the survivor or their
parents, it is possible to activate a personal account to
give the survivor access to view and/or print the elec-
tronic documents (summary treatment, brochures and
any other documents uploaded on the platform such as
radiotherapy files) in any of the available languages.
Electronic documents can thus be shared at any time
with the survivor’s physicians or hospitals where they
were admitted. The SurPass data can be modified only
by the healthcare providers with the appropriate cre-
dentials (at this stage, only the treating physicians). It is
however possible that survivors themselves can add
some more information in a dedicated section of the
online platform (e.g. visits, examinations, patient re-
ported outcome measures and other tests).3.4. Implementation and impact
The SurPass is being integrated in several paediatric
cancer centres as well as in some EU Member States’
National Cancer Plans. In 2015, it was included in the 5-
year Austrian cancer plan for paediatrics. In 2017, the
Italian Association of Paediatric Haematology and
Oncology (AIEOP) approved the SurPass for use in all
the AIEOP centres. Belgium, Croatia, Germany,
Lithuania, Portugal and Spain are considering its
implementation.For each survivor, the treatment summary can be
uploaded either manually by retrieving data from
hardcopies of their clinical record or electronically by
downloading data from databases used during the
treatment period (e.g. electronic clinical records, data-
bases of clinical trials in which the former patient was
enrolled or cancer registries). The electronic download
of data was tested in Italy, using the AIEOP-I-BFM
ALL 2009 protocol. After mapping of the variables in
common between the two databases, it was possible to
download 61% of the requested data (72% if only
mandatory fields were considered), thus reducing the
average time of 1.5 h to just 30 min for preparing the
SurPass for a standard risk leukemic patient.
A user manual is available either online or in paper
format. The treating physicians and/or authorised
personnel access the secured website (http://www.
survivorshippassport.org): and login with their personal
credentials. The first step is to insert the personal data
of the survivor to create his or her personal record.
Then, treatment data should be inserted following the
predefined forms of the web-based platform. The online
system performs automatic checks. After completion of
the treatment summary, built-in algorithms suggest
which recommendations should be given to the survivor.
However, the clinician can take into account other cir-
cumstances when finalising the decision about recom-
mendations and generating the electronic documents to
be delivered to the survivor.
Between 2012 and 2015, 314 SurPass documents were
delivered to CCS who had survived at least 5 years since
Table 1
Answers to selected items of the Likert questionnaire completed by 190 long-term survivors after having received the Survivorship Passport.
Question type and number Disagree Agree Overall score
Strongly
disagree N (%)
Disagree
N (%)
Slightly
disagree N (%)
Total disagree
N (%)
Slightly
agree N (%)
Agree
N (%)
Strongly
agree N (%)
Total agree
N (%)
Mean (sd) Median (IQ)
2. It has been useful to me to have a
recapitulatory interview when I was
given the Passport
0 2 (1.1) 1 (0.5) 3 (1.6) 6 (3.2) 77 (40.7) 103 (54.5) 186 (98.4) 5.5 (0.7) 6 (5e6)
3. It has been useful to me to have the
possibility of talking about the disease
for which I have been treated
2 (1.1) 1 (0.5) 1 (0.5) 4 (2.1) 11 (5.8) 88 (46.8) 85 (45.2) 184 (97.8) 5.3 (0.8) 5 (5e6)
6. I asked all questions in my mind
because I was not embarrasseda
6 (3.3) 8 (4.4) 7 (3.8) 21 (11.5) 6 (3.3) 65 (35.5) 91 (49.7) 162 (88.5) 5.1 (1.3) 5 (5e6)
8. My knowledge about the possible
consequences of the treatment I
received has changed
22 (12.2) 61 (33.9) 8 (4.4) 91 (50.5) 26 (14.4) 43 (23.9) 20 (11.1) 89 (49.4) 3.4 (1.7) 3 (2e5)
9. My concerns about the possible
complications related to the treatment
I received have not increaseda
13 (7.1) 18 (9.8) 24 (13.1) 55 (30.0) 15 (8.2) 65 (35.5) 48 (26.2) 128 (69.9) 4.3 (1.6) 5 (3e6)
11. It reassures me to know I have a
personalised schedule of control
examinations aimed at evaluating the
possible complications of the
treatment I received
0 2 (1.1) 2 (1.1) 4 (2.2) 7 (3.8) 75 (40.5) 99 (53.5) 181 (97.8) 5.4 (0.7) 6 (5e6)
13. The information I have been given
prompted me to change some aspects
of my life
16 (8.8) 29 (16.0) 15 (8.3) 60 (33.1) 27 (14.9) 60 (33.1) 34 (18.8) 121 (66.8) 4.1 (1.6) 5 (3e5)
14. After the examination and the
interview with physicians, I do not
have feelings of fear and/or anxiety
that I had not beforea
5 (2.8) 8 (4.5) 10 (5.6) 23 (12.9) 9 (5.1) 73 (41.1) 73 (41.1) 155 (87.3) 5.0 (1.2) 5 (5e6)
23. It is useful to have a written summary
report on my underlying disease and
on the treatment I received
0 3 (1.6) 0 3 (1.6) 1 (0.5) 54 (29.1) 128 (68.8) 183 (98.4) 5.6 (0.7) 6 (5e6)
24. The Passport has made me more aware
of prevention aspects related to my
health
6 (3.3) 11 (5.9) 12 (6.5) 29 (15.7) 31 (16.8) 73 (39.7) 51 (27.7) 155 (84.2) 4.7 (1.3) 5 (4e6)
27. The Passport has allowed a more
effective communication with my
family doctor or with physicians from
other hospitals
2 (1.1) 7 (3.8) 6 (3.3) 15 (8.2) 27 (14.7) 85 (46.2) 57 (31.0) 169 (91.9) 4.9 (1.1) 5 (5e6)
a The original question has been reversed for ease of data reporting.
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R. Haupt et al. / European Journal of Cancer 102 (2018) 69e8178the end of treatment, were in regular follow-up and had
attended the late effects clinic of Istituto Giannina
Gaslini in Italy. All received the Likert questionnaire
and 190 (61%) participated in the survey; details of the
results will be published separately. In general
(Supplemental Table 2), there were no differences in
demographic, type of diagnosis and interval between
SurPass delivery and date of diagnosis between those
who responded and those who did not respond to the
questionnaire. Respondents were 96 males and 94 fe-
males with a median age at follow-up of 17.1 years (Inter
Quartile Range (IQR) 12.8e23.0) and a median follow-
up since end of treatment of 9 years (IQR 6e15). The
questionnaire was completed by the survivors them-
selves in 71 cases with a median age of 22.6 years (IQR
20.5e26.1), by the survivor and his/her parents in 56
cases with a median age of 15.6 years (IQR
13.2e18.6) and by parents in 49 cases with a median age
of 11.92 years (IQR 8.1e13.1). Table 1 reports on results
of selected answers to the questionnaire. Overall, 98.4%
of survivors or their families agreed or strongly agreed
on the benefit of receiving the SurPass. Increased
awareness about their health status and need for follow-
up was reported by 49.4% of the CCS, and 66.8% re-
ported modifications in their lifestyle; 91.9% shared the
SurPass with their family doctor. However, 30.1% of
survivors reported some increase in anxiety related to
possible health consequences [22].4. Discussion
Evidence exists that if follow-up is extended up to early
adulthood, as many as two-thirds of CCS may experi-
ence one or more chronic health condition that can be
severe or life-threatening [5,1,6,23] and that the preva-
lence of these conditions among CCS is much higher
than expected in the general population [7]. It is thus of
great importance that paediatric oncologists ensure that
the national health systems implement services and
strategies to carefully monitor these patients well
beyond the paediatric age. Primary and secondary pre-
vention strategies need to be set up to try to avoid late
effects, or at least aid their early diagnosis. These mea-
sures may improve quality of life for CCS and eventu-
ally reduce the financial burden that these chronic
conditions cause for health services.
The experience of long-term survivors in Europe is
extremely variable, both within a country but especially
between countries [24,25]. Not all survivors, in partic-
ular those treated many years ago, are aware or have
adequate information of possible late effects and of their
risks. There is not enough knowledge about screening
investigations (what, when and why are they necessary),
and survivors report fewer contacts with experts in the
field e ‘don’t know where to go’, ‘lost in follow-up’
[25,26]. Nowadays, most paediatric oncologists ensurethat adequate information on treatments, risks and
prevention opportunities is provided to all CCS at the
end of treatment and again at the time of transition to
adult care [10,11]. It should, however, be recognised that
the impact of the delivery of care plans in the post-
treatment period still needs to be further assessed. A
recent systematic review of studies addressing this issue
[27] has shown only a minimal evidence of a beneficial
effect that mainly refers to quality of life measures, but
not on distal health outcomes. Further research is still
needed since great variability was evident across the
study’s design as well as target population.
From this premise and with strong support of CCI
members, the idea of providing a SurPass to each child and
adolescent treated for cancerwas developed. The initiative
was further inspired by both the ‘Passport for Care’ (PFC)
project developed by the Children’s Oncology Group in
the United States (www.cancersurvivor.passportforcare.
org) [28] and by the Erice Statement [11], which specified
that it is the responsibility of the paediatric cancer unit to
provide the survivor and parents with a summary of the
characteristics of the disease, of the treatments
received and of the late complications that may occur.
While the PFC and SurPass are quite similar initia-
tives, they differ in that the SurPass has been developed
to meet the needs of all European CCS and has therefore
been made available in many European languages. The
SurPass’ strong link with the guidelines developed by the
IGHG make it ideally suited for use in multiple coun-
tries. In addition, the SurPass has a built-in follow-up
form, which may allow for the collection of information
about the results of the screening tests during follow-up
in a standardised format. This information could even-
tually provide statistics about the prevalence and/or
incidence of chronic conditions or second malignant
neoplasms in the long-term survivor population and
could be used at the institutional level or shared with
other national or international groups through cooper-
ative projects.
The aim of developing the SurPass was to not only
provide an online tool but also offer a personalised and
integrated healthcare resource to improve the quality of
life of former childhood cancer patients through more
effective monitoring of their long-term health. They
would be provided with guidance for their ‘transition’
into adult healthcare, empowering them to be respon-
sible for their own well-being and preventing adverse
events whenever possible. We hope that this tool will be
appreciated in particular in this young and mobile
population, which nowadays is much more likely to
move either within but also between countries. Survivors
own their SurPass and decide whether or not to share it
with other people. In particular, we believe that the
SurPass may also be a useful guide for those general
practitioners who have less experience in, and knowl-
edge about, possible late complications occurring in this
relatively rare, new and growing population.
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SurPass to be used for research purposes. In fact, if
survivors also consent to the follow-up form, it might be
possible, either at institutional or even larger level, to
collect statistics about who has done what in terms of
screening and the corresponding results. Statistics could
then be provided about prevalence and/or incidence and
analysis performed on risk factors of chronic conditions
detected following evidence-based screening
recommendations.
This tool has already been tested in a few institutions
and has received mostly positive feedback from CCS.
However, our ‘customer satisfaction’ questionnaire
showed that although for most subjects the SurPass
delivery had a positive impact, in some survivors it
increased the level of anxiety related to possible side-
effects. We believe that careful strategies to improve the
communication of health risks are needed to avoid an
unnecessary psychological burden on survivors. We plan
to further build on the questionnaire and continue to
evaluate the use and impact of the SurPass in each
centre which will be issuing it. The SurPass should
ideally not stand on its own but be an integrated part of
a system of LTFU thereby assuring a point-of-contact
for CCS in need of support. Communications should be
tailored to each CCS taking into account their cultural,
emotional, cognitive and psychological background [11].
While there is a need to communicate sensitive clinical
aspects to a survivor of childhood cancer without
generating unnecessary anxiety, there is also a need for
clear and accurate medical language which can be un-
derstood by any healthcare professional who needs to
access this information.
We recognise that the preparation of each SurPass
might be quite time consuming. This is the case partic-
ularly if the treatment summary is entered manually by
retrieving data from hard copies of the clinical record.
However, we have shown that recovering data from
databases used during the treatment period (e.g. elec-
tronic clinical records, databases of clinical trials in
which the former patient was enrolled or cancer regis-
tries) is also feasible. This procedure requires that a
mapping procedure be performed to associate variables
between each clinical trial or institutional electronic
clinical record database and the SurPass. This process
may require some extra time but, once done, it can be
useful for all former patients whose data are stored in
that specific database.
Importantly, because of quality control issues, final
data from clinical trials might not be available until
several years after treatment completion. In addition,
there may be data protection and informed consent is-
sues to be considered when aiming to retrieve clinical
trial data in retrospect other than initially planned.
While historic radiotherapy requires manual review and
entry, future developments should integrate modern
electronic radiotherapy records.International codes have been adopted wherever
possible for homogeneity purposes to allow multi-
language translation and to facilitate the preparation of
built-in algorithms. The radiotherapy coding system we
have devised is based on treatments given in the era
before 1995e2000. Most longer term survivors now
troubled by late effects were treated in this era at a time
before it was possible to measure dose to individual or-
gans. Similarly, current guidelines for follow-up are
based on available evidence, also usually from older
data. Information about the radiotherapy given to sur-
vivors treated several years ago can be imprecise, but
even ‘basic’ information is important (e.g. to know that
some radiotherapy to the chest was received). Current
guidelines do not use the OAR dose to estimate the risk
for a specific side-effect (e.g. secondary breast cancer) but
mostly use broad areas of the body that received radio-
therapy (e.g. chest). When more detailed information on
exposures to certain OAR is available, this can already
be uploaded into the SurPass platform. This information
might be of interest in the future for clinical purposes,
e.g. local tumour relapse or for new guideline-specific
risk stratification and surveillance recommendations.
Another important issue we had to deal with was that
the SurPass platform contains personal data that need
protection according to national and international privacy
regulations. Based on local/national circumstances, it is
possible to have data stored in the Cineca data centre or in
a local certified data centre in the country that wants to
adopt the SurPass platform. Any data center should
anyway guarantee the highest level standards of security
and privacy according to the European Directive 2016/
679. In addition, ad hoc solutions can be implemented in
the case of constraints that are more stringent. During the
ExPO-r-Net project, a pseudo-anonymisation service,
called EUPID (European Patient Identity Manage-
mentdhttps://eupid.eu),was developedbyproject partner
Austrian Institute of Technology, and it has been
integrated into the SurPass platform [29].
TheEuropeanSociety for PaediatricOncology (SIOPE)
has continuously supported the SurPass initiative since its
inclusion in the ENCCA, ExPO-r-Net and PanCar-
eSurFup projects and has included the SurPass in the
SIOPE Strategic Plan ‘A European Cancer Plan for Chil-
dren and Adolescents’ (https://www.siope.eu/SIOPE_
StrategicPlan2015/) [30]. More importantly, SIOPE sup-
ports the European National Paediatric Haemato-
Oncology Societies in liaising with health ministries to
ensure that this model will be effectively adopted and
introduced intonationalhealthcare systems inEurope.The
SurPass project has also been integrated in the European
Reference Network for Paediatric Cancers (ERN Paed-
Can, paedcan.ern-net.eu) launched inDecember2016.This
ERN PaedCan will establish a clear framework for Euro-
pean healthcare providers to provide equal access to
healthcareacrossborders andwill includeavirtualnetwork
of late effect experts. More recently, the SurPass initiative
R. Haupt et al. / European Journal of Cancer 102 (2018) 69e8180was also included in the Joint Action on Rare Cancers
(jointactionrarecancers.eu), which will consolidate further
the guidelines on models of healthcare for survivors of
childhood cancers developed by PanCare partners.
In conclusion, we believe that the implementation of
this innovative tool, the SurPass, at the institutional,
regional or national level will represent a sustainable
solution for national healthcare systems to systemati-
cally organise LTFU care in a consistent and cost-
effective way. This innovative tool can provide a more
homogeneous follow-up and screening of all European
CCS. This will result in more efficient use of health
systems’ economic resources by avoiding unnecessary
examinations and possibly prevent or delay the occur-
rence of severe chronic conditions that might further
increase the personal, socioeconomic and psychosocial
burdens faced by CCS.
To obtain access to a test version of the Survivorship
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